(AOF) – Predilife, a specialist in innovative pathology risk prediction solutions for personalized medicine, achieved a sales volume of 370,000 euros in 2022, i.e. a multiplication by 2.6 compared to 2021 after the tripling of sales in first semester.
The company believes that the growth of its customer base in business sectors as varied as finance (Allianz, Europe’s leading insurer), agri-food (Lactalis) or the media (TF1) “demonstrates the growing appetite of companies for personalized medicine as close as possible to the health of employees”.
AOF – LEARN MORE
Find out more about the “pharmacy” sector
Loss of speed in European research
European research is losing ground to American and Chinese research. In twenty years, Europe’s share has fallen from 41% to 31% in global R&D. China’s share jumped from 1% to 8%. As for the United States, which supplanted Europe, in 2001 it devoted only 2 billion euros per year more than Europe to R&D, whereas now this gap has reached 25 billion! Some experts accuse the European authorities of not having deployed effective policies. The financing of pharmaceutical research should therefore have been better targeted via the “Horizon 2020” programme. France only comes in eighteenth position in European funding despite the quality of its research. Conversely, the United States concentrates funding on Boston and a few centers of excellence.